MX2017004842A - Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica). - Google Patents
Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica).Info
- Publication number
- MX2017004842A MX2017004842A MX2017004842A MX2017004842A MX2017004842A MX 2017004842 A MX2017004842 A MX 2017004842A MX 2017004842 A MX2017004842 A MX 2017004842A MX 2017004842 A MX2017004842 A MX 2017004842A MX 2017004842 A MX2017004842 A MX 2017004842A
- Authority
- MX
- Mexico
- Prior art keywords
- levosimendan
- motor neuron
- als
- neuron diseases
- treatment
- Prior art date
Links
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 title abstract 3
- 229960000692 levosimendan Drugs 0.000 title abstract 3
- 208000005264 motor neuron disease Diseases 0.000 title abstract 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método para tratar enfermedades de las neuronas motoras tal como esclerosis lateral amiotrófica (ALS) utilizando levosimendán o su metabolito activo (II) como un ingrediente activo. El levosimendán o su metabolito activo (II) son capaces de aliviar la pérdida de fuerza o la función muscular asociada con enfermedades de las neuronas motoras.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20140278 | 2014-10-15 | ||
| PCT/FI2015/000039 WO2016059287A1 (en) | 2014-10-15 | 2015-10-14 | Levosimendan for use in the treatment of motor neuron diseases (e.g. als) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004842A true MX2017004842A (es) | 2017-06-22 |
| MX380502B MX380502B (es) | 2025-03-12 |
Family
ID=54705650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004842A MX380502B (es) | 2014-10-15 | 2015-10-14 | Levosimendán para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrófica). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10357492B2 (es) |
| EP (1) | EP3206690A1 (es) |
| JP (1) | JP6688295B2 (es) |
| KR (1) | KR102560182B1 (es) |
| CN (1) | CN107072994B (es) |
| AU (1) | AU2015332367B2 (es) |
| CA (1) | CA2963179C (es) |
| MX (1) | MX380502B (es) |
| NZ (1) | NZ729803A (es) |
| RU (1) | RU2706001C2 (es) |
| WO (1) | WO2016059287A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3145456A1 (en) | 2019-07-01 | 2021-01-07 | Orion Corporation | Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide |
| JP7618237B2 (ja) * | 2019-10-16 | 2025-01-21 | 国立大学法人京都大学 | 運動神経細胞変性阻害剤 |
| AU2020408323A1 (en) | 2019-12-16 | 2022-08-11 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF) |
| CN115518037A (zh) * | 2022-10-14 | 2022-12-27 | 上药东英（江苏）药业有限公司 | 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20011465A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Pyridatsinonijohdannaisen uusi käyttö |
| UA115968C2 (uk) * | 2011-03-01 | 2018-01-25 | Фарнекст | Нові композиції для лікування неврологічних захворювань |
| US9867837B2 (en) * | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
-
2015
- 2015-10-14 CA CA2963179A patent/CA2963179C/en active Active
- 2015-10-14 RU RU2017116157A patent/RU2706001C2/ru active
- 2015-10-14 US US15/518,949 patent/US10357492B2/en active Active
- 2015-10-14 JP JP2017519906A patent/JP6688295B2/ja active Active
- 2015-10-14 AU AU2015332367A patent/AU2015332367B2/en active Active
- 2015-10-14 MX MX2017004842A patent/MX380502B/es unknown
- 2015-10-14 WO PCT/FI2015/000039 patent/WO2016059287A1/en not_active Ceased
- 2015-10-14 NZ NZ729803A patent/NZ729803A/en unknown
- 2015-10-14 KR KR1020177012960A patent/KR102560182B1/ko active Active
- 2015-10-14 CN CN201580055558.2A patent/CN107072994B/zh active Active
- 2015-10-14 EP EP15801474.6A patent/EP3206690A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NZ729803A (en) | 2023-07-28 |
| CA2963179A1 (en) | 2016-04-21 |
| AU2015332367B2 (en) | 2020-05-14 |
| US20170231987A1 (en) | 2017-08-17 |
| AU2015332367A1 (en) | 2017-04-06 |
| US10357492B2 (en) | 2019-07-23 |
| JP6688295B2 (ja) | 2020-04-28 |
| RU2017116157A (ru) | 2018-11-15 |
| WO2016059287A1 (en) | 2016-04-21 |
| CN107072994A (zh) | 2017-08-18 |
| RU2017116157A3 (es) | 2019-04-11 |
| RU2706001C2 (ru) | 2019-11-13 |
| KR20170066647A (ko) | 2017-06-14 |
| EP3206690A1 (en) | 2017-08-23 |
| CN107072994B (zh) | 2020-04-21 |
| JP2017531006A (ja) | 2017-10-19 |
| KR102560182B1 (ko) | 2023-07-28 |
| CA2963179C (en) | 2023-08-29 |
| MX380502B (es) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| TN2018000005A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2017010150A (es) | Bacterias probioticas recombinantes. | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| MY179105A (en) | Methods of treating alzheimer's disease | |
| PH12017501990B1 (en) | Imidazopyrazinones as pde1 inhibitors | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2017000306A (es) | Metodos para tratar hipotension. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2017004842A (es) | Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica). | |
| TW201613610A (en) | Use of ginsenoside M1 for treating lupus nephritis | |
| EP3738559B8 (de) | System zur augentherapie mittels gewebebearbeitung durch nichtlineare wechselwirkung | |
| PH12017501872A1 (en) | Methods of treating diseases | |
| ZA201903804B (en) | Method for producing hydrophobising leather treatment agents | |
| TW201613569A (en) | Composition consisting of kukoamine A and/or kukoamine B and method of using thereof | |
| EP3244897A4 (en) | Methods for treating alzheimer's disease | |
| HK1242214A1 (en) | Levosimendan for use in the treatment of motor neuron diseases (e. g. als) | |
| PH12018500339A1 (en) | Lysobactin for use in the treatment of bovine mastitis | |
| PT3270913T (pt) | Citalopram ou escitalopram para utilização no tratamento de doenças neurodegenerativas | |
| EP3125912A4 (en) | Method for treating or enhancing muscle tissue | |
| PT3609486T (pt) | Sarpogrelato para uso num método para o tratamento de doença cardíaca em mamíferos | |
| HK1240079A1 (en) | Method for treating hyperhidrosis | |
| AU2015902286A0 (en) | Method Of Treating Crohn's Disease | |
| MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci |